Dimensional Fund Advisors LP Purchases 80,116 Shares of CONMED Corporation $CNMD

Key Points

• Dimensional Fund Advisors increased its CONMED position by 6.1%. The firm acquired 80,116 shares, bringing its total holdings to 1.39 million shares worth approximately $49.25 million, or 4.63% of the company.
• Other institutional investors also expanded their exposure, including Invenomic Capital Management, which increased its stake by 75.6%, and Allspring Global Investments, which raised its holdings by 39.9%.
• CONMED exceeded second-quarter expectations with adjusted EPS of $1.38 and revenue of $343.5 million, while maintaining 2026 EPS guidance of $4.48 to $4.60. Despite some analyst price-target increases, the consensus rating remains “Reduce,” with a $41.40 target.

Dimensional Fund Advisors LP lifted its position in shares of CONMED Corporation (NYSE:CNMD - Free Report) by 6.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,392,920 shares of the company's stock after acquiring an additional 80,116 shares during the quarter. Dimensional Fund Advisors LP owned approximately 4.63% of CONMED worth $49,250,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wasatch Advisors LP bought a new position in CONMED in the third quarter valued at about $47,026,000. Invenomic Capital Management LP boosted its stake in shares of CONMED by 75.6% during the fourth quarter. Invenomic Capital Management LP now owns 737,546 shares of the company's stock valued at $29,944,000 after purchasing an additional 317,543 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of CONMED during the fourth quarter worth about $9,029,000. Millennium Management LLC bought a new stake in shares of CONMED during the third quarter worth about $9,239,000. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of CONMED by 39.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 582,733 shares of the company's stock valued at $20,705,000 after buying an additional 166,301 shares during the period.

Trending Headlines about CONMED

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q2 results exceeded expectations. CONMED reported adjusted EPS of $1.38, above the $1.10 consensus estimate and up from $1.15 a year earlier. Revenue reached $343.5 million, surpassing the $337.6 million forecast. CONMED Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised and reaffirmed an above-consensus outlook. CONMED forecast 2026 adjusted EPS of $4.48 to $4.60, compared with analyst expectations near $4.37, while targeting 5% to 6% organic growth. Gross-margin expansion and solid international sales also supported the improved outlook. CONMED 2026 Guidance
• Positive Sentiment: Analysts increased price targets. Wells Fargo raised its target to $46 from $39, and Piper Sandler lifted its target to $45 from $39, reflecting greater confidence following the quarterly performance. Analyst Price Target Changes
• Neutral Sentiment: Management’s earnings presentation and call highlighted the quarter’s operating performance and 2026 growth priorities. The materials provide additional detail on the earnings beat, margins and guidance but do not indicate a major change to the company’s longer-term strategy. CONMED 2026 Q2 Earnings Presentation
• Negative Sentiment: Valuation and limited analyst upside may be weighing on the stock. Piper Sandler maintained a Neutral rating with a $45 target, while Wells Fargo kept an Equal Weight rating at $46—both below or near the recent trading level. Revenue growth was also modest at approximately 0.3% year over year, despite the earnings beat.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a "sell (d)" rating on shares of CONMED in a report on Thursday, June 4th. JPMorgan Chase & Co. reduced their target price on shares of CONMED from $43.00 to $40.00 and set a "neutral" rating on the stock in a report on Thursday, April 30th. Wells Fargo & Company upped their price target on shares of CONMED from $39.00 to $46.00 and gave the company an "equal weight" rating in a research report on Thursday. Needham & Company LLC reaffirmed a "hold" rating on shares of CONMED in a research note on Monday, July 13th. Finally, Zacks Research lowered shares of CONMED from a "hold" rating to a "strong sell" rating in a report on Monday, July 13th. Five research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Reduce" and a consensus target price of $41.40.

CONMED Price Performance

CONMED stock opened at $46.38 on Monday. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of 25.07, a PEG ratio of 2.11 and a beta of 0.93. CONMED Corporation has a 52-week low of $31.44 and a 52-week high of $56.63. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.69 and a current ratio of 1.48. The stock's 50 day moving average price is $37.27 and its two-hundred day moving average price is $38.44.

CONMED (NYSE:CNMD - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.27. CONMED had a net margin of 4.12% and a return on equity of 14.31%. The company had revenue of $343.49 million during the quarter, compared to analyst estimates of $337.60 million. During the same quarter in the previous year, the business posted $1.15 EPS. CONMED's revenue for the quarter was up .3% compared to the same quarter last year. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. On average, equities analysts predict that CONMED Corporation will post 4.54 earnings per share for the current year.

CONMED Profile

CONMED Corporation NYSE: CNMD is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company's product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.